Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. Journal Published:
PUBLICATION TYPE: Journal Article
Journal: JAMA : the journal of the American Medical Associa
VOLUME: 299
Page Numbers: 1474-6
Journal Abbreviation: JAMA
ISSN: 1538-3598
DAY: 26
MONTH: Mar
YEAR: 2008
Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 7501160
Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
AFFILIATION: Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington 98101, USA. psaty@u.washington.edu
Country: United States
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: JAMA
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs Related Publications